Passive immunotherapy of cancer in animals and man.

Published on Jan 1, 1977in Advances in Cancer Research4.667
· DOI :10.1016/S0065-230X(08)60637-5
Steven A. Rosenberg196
Estimated H-index: 196
(NIH: National Institutes of Health),
William D. Terry42
Estimated H-index: 42
(NIH: National Institutes of Health)
Publisher Summary Immunologic manipulations to control tumor growth can essentially be divided into passive and active categories. Passive immunotherapy refers to approaches in which immunologic reagents, such as serum, cells, or cell products that are thought to have antitumor activity, are administered to a tumor-bearing host. This chapter reviews recent studies of the use of passive immunotherapy for the treatment of cancer in animals and man. Immune depression in cancer patients has been well documented and attempts to actively stimulate both nonspecific and specific antitumor immune reactions in cancer patients is generally let down by intrinsic defects in the ability of the host to respond. The passive administration of immune reagents can be capable of reacting against the tumor independent of the host's immune competence. Therefore, passive therapy is regarded as an attractive area of investigation in tumor immunotherapy. The chapter summarizes the existing information concerning the use of subcellular products, such as immune RNA or transfer factor, in the treatment of animal and human malignancy. It is noted that because of immunodepression caused by cancer treatments, passive immunotherapy is considered independent of host immune competence, and is therefore an ideal candidate for inclusion in combined-modality approaches to cancer therapy.
  • References (212)
  • Citations (195)
📖 Papers frequently viewed together
1,935 Citations
2,122 Citations
1,418 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Robert C. BastH-Index: 108
#2Berton ZbarH-Index: 83
Last. Herbert J. RappH-Index: 42
view all 4 authors...
CLINICAL evaluation of BCG for the treatment of cancer is under way in at least 50 centers throughout the world. Use of BCG in such cases has been encouraged by work with animal tumors indicating that BCG treatment can modify the action of carcinogens, prevent growth of tumor transplants and eliminate established tumors. In some reports BCG has not been effective or has even enhanced tumor growth. Sufficient data are now available to identify at least some of the factors that contribute to the s...
237 CitationsSource
#1C. T. C. Kennedy (University of Cambridge)H-Index: 1
#2D. B. Cater (University of Cambridge)H-Index: 1
Last. F. Hartveit (University of Cambridge)H-Index: 1
view all 3 authors...
19 CitationsSource
34 Citations
#1M.V. JenkinsH-Index: 1
#2N. PolanskaH-Index: 1
Last. M.R. WillsH-Index: 1
view all 3 authors...
39 Citations
#1Yosef H. Pilch (UCLA: University of California, Los Angeles)H-Index: 25
#2Dieter Fritze (Heidelberg University)H-Index: 1
Last. David H. Kern (UCLA: University of California, Los Angeles)H-Index: 22
view all 3 authors...
16 CitationsSource
#1Albert F. LoBuglio (OSU: Ohio State University)H-Index: 24
#2James A. Neidhart (OSU: Ohio State University)H-Index: 16
: This review has attempted to describe the characteristics of transfer factor which make it a very attractive potential agent for immunotherapy. Preliminary observations suggest that it may be capable of modifying resistance to a variety of diseases including cancer but considerable progress in basic knowledge regarding this agent is crucial to its successful application in clinical disease states. Fortunately, a sizable number of interested and dedicated investigators are exploring these diffi...
9 CitationsSource
#1P. W. Wright (UW: University of Washington)H-Index: 7
#2Karl Erik Hellström (UW: University of Washington)H-Index: 73
Last. Irwin D. Bernstein (UW: University of Washington)H-Index: 50
view all 4 authors...
27 CitationsSource
#1R.Mark Vetto (UO: University of Oregon)H-Index: 15
#2Denis R. Burger (UO: University of Oregon)H-Index: 11
Last. Harvey W. Baker (UO: University of Oregon)H-Index: 3
view all 5 authors...
The objective of this study was to utilize transfer factor to stimulate cell-mediated immunity to specific tumor antigens in cancer patients. Thirty-five selected patients with advanced recurrent cancer, who were not suitable for further conventional therapy, were treated with transfer factor. Transfer factor was prepared from cohabitants of the patients and administered at 2-week intervals. This immunotherapeutic approach produced a clinical effect in 13 patients in terms of regression of tumor...
23 CitationsSource
#1Lal SH-Index: 1
#2Simon N. YoungH-Index: 55
Last. Sourkes TlH-Index: 1
view all 3 authors...
193 Citations
: A three-step treatment plan incorporating adoptive immunotherapy and chemoradiotherapy was used to treat AKR (H-2k) mice bearing spontaneous leukemia-lymphoma (SLL). 1) Leukemic mice were treated with chemoradiotherapy for immunosuppression and leukemia cytoreduction. 2) To introduce a graft-versus-leukemia reaction against residual malignant cells, the immunosuppressed AKR mice were given immunocompetent cells from H-2 mismatched DBA/2 (H-2d) donors. 3) To "rescue" the AKR hosts from incipien...
11 CitationsSource
Cited By195
#1Meagan R. Rollins (UMN: University of Minnesota)
#2Ellen J. Spartz (UMN: University of Minnesota)H-Index: 1
Last. Ingunn M. Stromnes (UMN: University of Minnesota)H-Index: 23
view all 3 authors...
: T lymphocytes are capable of specific recognition and elimination of target cells. Physiological antigen recognition is mediated by the T cell receptor (TCR), which is an alpha beta heterodimer comprising the products of randomly rearranged V, D, and J genes. The exquisite specificity and functionality of T cells can be leveraged for cancer therapy: specifically, the adoptive transfer of T cells that express tumor-reactive TCRs can induce regression of solid tumors in patients with advanced ca...
#1Meysam Mosallaei (IUMS: Isfahan University of Medical Sciences)H-Index: 2
#2Miganoosh Simonian (Tehran University of Medical Sciences)
Last. Rasoul Salehi (IUMS: Isfahan University of Medical Sciences)H-Index: 22
view all 7 authors...
Cancer immunotherapy emerged as a novel therapeutic option that employs enhanced or amended native immune system to create a robust response against malignant cells. The systemic therapies with immune-stimulating cytokines have resulted in substantial dose-limiting toxicities. Targeted cytokine immunotherapy is being explored to overcome the heterogeneity of malignant cells and tumor cell defense with a remarkable reduction of systemic side effects. Cell-based strategies, such as dendritic cells...
#1Evgenii L. GuryevH-Index: 3
#2Natalia VolodinaH-Index: 3
Last. Sergey M. Deyev (RAS: Russian Academy of Sciences)H-Index: 22
view all 14 authors...
We report combined therapy using upconversion nanoparticles (UCNP) coupled to two therapeutic agents: beta-emitting radionuclide yttrium-90 ( 90 Y) fractionally substituting yttrium in UCNP, and a fragment of the exotoxin A derived from Pseudomonas aeruginosa genetically fused with a targeting designed ankyrin repeat protein (DARPin) specific to HER2 receptors. The resultant hybrid complex UCNP-R-T was tested using human breast adenocarcinoma cells SK-BR-3 overexpressing HER2 receptors and immun...
9 CitationsSource
Arsenic and its various forms have been in use in ancient Chinese medicine for more than 2000 years. Arsenicals have gained importance for having remedial effects for various diseases from syphilis to cancer thus highlighting its role as a therapeutic agent even though it has been labelled as a potential ‘poison’. The ability of arsenic, specifically arsenic trioxide, to treat acute promyelocytic leukaemia has radically changed the perception of this poison and has been the main factor for the r...
14 CitationsSource
#1Michel SadelainH-Index: 1
Cancer immunotherapy is emerging as an effective and dependable approach to induce durable responses and survival benefit in several cancers. Two approaches, one based on antibody therapy to block immune inhibitory checkpoints and the other on the genetic engineering of T lymphocytes, have yielded dramatic clinical results in recent years, earning cancer immunotherapy the title “breakthrough of the year” by the journal Science in 2013. Based on the success of targeting CD19 in B cell malignancie...
9 CitationsSource
Abstract The earliest experimental trials of monoclonal antibodies took place in the early 1980s using murine monoclonal antibodies directed at human lymphoma and leukemia cell antigens. Since those early trials, therapeutic advances have produced monoclonal antibodies and fusion proteins that are now used in multiple disease states including cancers, autoimmune diseases, inflammatory bowel disease, psoriasis, neurologic disorders and others. Modern techniques have led to the development of mult...
2 CitationsSource
#1Michel Sadelain (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 79
The advent of second generation chimeric antigen receptors and the CD19 paradigm have ushered a new therapeutic modality in oncology. In contrast to earlier forms of adoptive cell therapy, which were based on the isolation and expansion of naturally occurring T cells, CAR therapy is based on the design and manufacture of engineered T cells with optimized properties. A new armamentarium, comprising not only CARs but also chimeric costimulatory receptors, chimeric cytokine receptors, inhibitory re...
37 CitationsSource
#1Simone MuenstH-Index: 10
#2Heinz Läubli (University of Basel)H-Index: 19
Last. Sylvia HoellerH-Index: 14
view all 6 authors...
The complicated interplay between cancer and the host immune system has been studied for decades. New insights into the human immune system as well as the mechanisms by which tumours evade immune control have led to the new and innovative therapeutic strategies that are considered amongst the medical breakthroughs of the last few years. Here, we will review the current understanding of cancer immunology in general, including immune surveillance and immunoediting, with a detailed look at immune c...
51 CitationsSource
#1Erik D. WoldH-Index: 7
#2Vaughn V. SmiderH-Index: 26
Last. Brunhilde H. Felding (Scripps Research Institute)H-Index: 7
view all 3 authors...
One of the newer classes of targeted cancer therapeutics is monoclonal antibodies. Monoclonal antibody therapeutics are a successful and rapidly expanding drug class due to their high specificity, activity, favourable pharmacokinetics, and standardized manufacturing processes. Antibodies are capable of recruiting the immune system to attack cancer cells through complement-dependent cytotoxicity or antibody dependent cellular cytotoxicity. In an ideal scenario the initial tumor cell destruction i...
5 CitationsSource